4.5 Article

miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1

期刊

MOLECULAR CANCER RESEARCH
卷 9, 期 1, 页码 25-35

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1541-7786.MCR-10-0497

关键词

-

资金

  1. NIH [5 T32 CA009666, P50 CA70907, CA132608, CA117965]
  2. David M. Sather Memorial Fund
  3. Armour Family Lung Cancer Research Fund
  4. Dan L. Duncan Cancer Center at Baylor College of Medicine
  5. ASCO Cancer Foundation
  6. International Association for the Study of Lung Cancer (IASLC)
  7. [P30 CA125123]
  8. NATIONAL CANCER INSTITUTE [P50CA070907, P30CA125123, R01CA132608, T32CA009666, R01CA181184, R01CA117965] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The microRNA-200 (miR-200) family is part of a gene expression signature that predicts poor prognosis in lung cancer patients. In a mouse model of K-ras/p53-mutant lung adenocarcinoma, miR-200 levels are suppressed in metastasis-prone tumor cells, and forced miR-200 expression inhibits tumor growth and metastasis, but the miR-200 target genes that drive lung tumorigenesis have not been fully elucidated. Here, we scanned the genome for putative miR-200 binding sites and found them in the 3'-untranslated region (3'-UTR) of 35 genes that are amplified in human cancer. Mining of a database of resected human lung adenocarcinomas revealed that the levels of one of these genes, Flt1/VEGFR1, correlate inversely with duration of survival. Forced miR-200 expression suppressed Flt1 levels in metastasis-prone lung adenocarcinoma cells derived from K-ras/p53-mutant mice, and negatively regulated the Flt1 3'-UTR in reporter assays. Cancer-associated fibroblasts (CAFs) isolated from murine lung adenocarcinomas secreted abundant VEGF and enhanced tumor cell invasion in coculture studies. CAF-induced tumor cell invasion was abrogated by VEGF neutralization or Flt1 knockdown in tumor cells. Flt1 knockdown decreased the growth and metastasis of tumor cells in syngeneic mice. We conclude that miR-200 suppresses lung tumorigenesis by targeting Flt1. Mol Cancer Res; 9(1); 25-35. (C) 2010 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据